Hormon Reseptörü Pozitif/Her2 Negatif Metastatik Meme Kanserinde Moleküler Mekanizma ve Güncel Tedavi Yaklaşımları

Yazarlar

Onur Alkan
https://orcid.org/0000-0002-8558-1654

Özet

Hormon reseptörü pozitif (HR-pozitif), insan epidermal büyüme faktörü reseptörü 2 negatif (HER2-negatif) metastatik meme kanserinde tedavi yaklaşımları, endokrin sinyal mekanizmalarının ve kazanılmış direnç yollarının daha iyi anlaşılmasıyla önemli ölçüde değişmiştir. Bu derlemede östrojen reseptörünün yapısı ve işlevi, ESR1 mutasyonları, PI3K–AKT–mTOR sinyal yolu, PTEN kaybı ve siklin D–CDK4/6–Rb ekseni üzerinden endokrin duyarlılık ve direnç mekanizmaları ele alınmaktadır. Endokrin tedaviler ve CDK4/6 inhibitörlerinin klinik konumu; yeni nesil oral selektif östrojen reseptörü yıkıcıları, proteoliz hedefleyen kimeralar ve PI3K, AKT ve mTOR inhibitörleriyle birlikte güncel klinik çalışma verileri ışığında değerlendirilmektedir. Güncel tedavi yaklaşımı, moleküler biyobelirteçlerin önceki tedavi öyküsü, endokrin duyarlılık, komorbiditeler ve tedaviye bağlı toksisitelerle birlikte değerlendirilmesini gerektirmektedir.

Referanslar

Ben-Ari E. National Cancer Institute. Imaging Test Could Help Guide Breast Cancer Treatment Decisions. 2021. (25/09/2026 tarihinde https://www.cancer.gov/news-events/cancer-currents-blog/2021/breast-cancer-imaging-test-ffnp-hormone-therapy-response adresinden ulaşılmıştır).

Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine. 2017;377(19):1836–1846. doi:10.1056/NEJMoa1701830

Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology. 2010;28(20):3271–3277. doi:10.1200/JCO.2009.25.9820

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). The Breast. 2024;76:103756. doi:10.1016/j.breast.2024.103756

Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2021;39(35):3959–3977. doi:10.1200/JCO.21.01392

National Cancer Institute. Hormone Therapy for Breast Cancer. (25/09/2026 tarihinde https://www.cancer.gov/types/breast/treatment/hormone-therapy adresinden ulaşılmıştır).

Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986;320(6058):134–139. doi:10.1038/320134a0

Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389(6652):753–758. doi:10.1038/39645

National Library of Medicine. DailyMed. VEPPANU—vepdegestrant tablet: prescribing information. 2026. (30/09/2026 tarihinde https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=751e18d5-1d41-4b67-b1f3-10272ca5312d adresinden ulaşılmıştır).

Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics. 2013;45(12):1439–1445. doi:10.1038/ng.2822

Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of Clinical Oncology. 2022;40(28):3246–3256. doi:10.1200/JCO.22.00338

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412

André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine. 2019;380(20):1929–1940. doi:10.1056/NEJMoa1813904

Turner NC, Im SA, Saura C, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. New England Journal of Medicine. 2024;391(17):1584–1596. doi:10.1056/NEJMoa2404625

Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Journal of Biological Chemistry. 1998;273(22):13375–13378. doi:10.1074/jbc.273.22.13375

Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine. 2023;388(22):2058–2070. doi:10.1056/NEJMoa2214131

U.S. Food and Drug Administration. FDA approves capivasertib with fulvestrant for breast cancer. 2023. (25/09/2026 tarihinde https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer adresinden ulaşılmıştır).

Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine. 2012;366(6):520–529. doi:10.1056/NEJMoa1109653

Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Advances in Therapy. 2013;30(10):870–884. doi:10.1007/s12325-013-0060-1

Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research. 2009;11(5):R77. doi:10.1186/bcr2419

Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 2016;388(10063):2997–3005. doi:10.1016/S0140-6736(16)32389-3

Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine. 2022;386(10):942–950. doi:10.1056/NEJMoa2114663

Slamon DJ, Diéras V, Rugo HS, et al. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. Journal of Clinical Oncology. 2024;42(9):994–1000. doi:10.1200/JCO.23.00137

Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2-negative advanced breast cancer: final overall survival results of MONARCH 3. Annals of Oncology. 2024;35(8):718–727. doi:10.1016/j.annonc.2024.04.013

National Library of Medicine. DailyMed. VERZENIO—abemaciclib tablet: prescribing information. 2026. (25/09/2026 tarihinde https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06 adresinden ulaşılmıştır).

Kalinsky K, Bianchini G, Hamilton E, et al. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. Journal of Clinical Oncology. 2025;43(9):1101–1112. doi:10.1200/JCO-24-02086

U.S. Food and Drug Administration. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. 2023. (25/09/2026 tarihinde https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer adresinden ulaşılmıştır).

U.S. Food and Drug Administration. ORSERDU (elacestrant): prescribing information. 2023. (25/09/2026 tarihinde https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf adresinden ulaşılmıştır).

Campone M, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. New England Journal of Medicine. 2025;393(6):556–568. doi:10.1056/NEJMoa2505725

U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. 2026. (25/09/2026 tarihinde https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast adresinden ulaşılmıştır).

Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. New England Journal of Medicine. 2025;392(12):1189–1202. doi:10.1056/NEJMoa2410858

U.S. Food and Drug Administration. FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. 2025. (25/09/2026 tarihinde https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast adresinden ulaşılmıştır).

U.S. Food and Drug Administration. FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. 2026. (25/09/2026 tarihinde https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or adresinden ulaşılmıştır).

Martín M, Lim E, Chavez-MacGregor M, et al. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of Clinical Oncology. 2024;42(18):2149–2160. doi:10.1200/JCO.23.01500

Roche. FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer. 2026. (25/09/2026 tarihinde https://www.roche.com/media/releases/med-cor-2026-02-20 adresinden ulaşılmıştır).

Roche. Roche provides update on phase III persevERA study in ER-positive advanced breast cancer. 2026. (25/09/2026 tarihinde https://www.roche.com/media/releases/med-cor-2026-03-09 adresinden ulaşılmıştır).

Bidard FC, Mayer EL, Park YH, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. New England Journal of Medicine. 2025;393(6):569–580. doi:10.1056/NEJMoa2502929

U.S. Food and Drug Administration. FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. 2026. (25/09/2026 tarihinde https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative adresinden ulaşılmıştır).

Jhaveri KL, Im SA, Saura C, et al. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. New England Journal of Medicine. 2025;393(2):151–161. doi:10.1056/NEJMoa2501796

Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. The Lancet Oncology. 2017;18(5):654–662. doi:10.1016/S1470-2045(17)30109-2

Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2022;33(8):750–768. doi:10.1016/j.annonc.2022.05.520

Turner NC, Mayer EL, Park YH, et al. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Oncology. 2026;27(8):941–958. doi:10.1016/S1470-2045(26)00287-1

Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. Journal of Clinical Oncology. 2012;30(6):587–592. doi:10.1200/JCO.2010.33.5232

Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update. Journal of Clinical Oncology. 2023;41(22):3867–3872. doi:10.1200/JCO.22.02864

U.S. Food and Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer. 2025. (30/09/2026 tarihinde https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2 adresinden ulaşılmıştır).

Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450

Bardia A, Hu X, Dent R, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine. 2024;391(22):2110–2122. doi:10.1056/NEJMoa2407086

National Library of Medicine. DailyMed. ENHERTU—fam-trastuzumab deruxtecan-nxki: prescribing information. 2026. (30/09/2026 tarihinde https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6 adresinden ulaşılmıştır).

Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2023;402:1423–1433. doi:10.1016/S0140-6736(23)01245-X

National Cancer Institute. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors (NCT06257264). (25/09/2026 tarihinde https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-03104 adresinden ulaşılmıştır).

Yayınlanan

16 Kasım 2026

Lisans

Lisans